Home › Stocks › EUCRU

EUCRU — EUCRATES BIOMEDICAL ACQU COR

Reported value held$7.40M
Funds holding (latest)3
Sector—

EUCRU (EUCRATES BIOMEDICAL ACQU COR) is tracked on HoldingsHub across five years of quarterly 13F filings. 3 funds have reported positions historically, with the sum of their latest reported stakes valued at $7.40M. No fund in our coverage reported a position in the latest filing period, which typically means the stock has fallen out of the tracked funds' portfolios rather than that it cannot be bought.

All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.

Q4 2022 — 1 funds

FundSharesValuePortfolio WeightChange
UBS Group AG history 400 $3.94K 0.00% New

Q2 2022 — 1 funds

FundSharesValuePortfolio WeightChange
UBS Group AG history 199 $2.00K 0.00% Reduce

Q1 2022 — 1 funds

FundSharesValuePortfolio WeightChange
UBS Group AG history 799 $8.00K 0.00% Add

Q4 2021 — 3 funds

FundSharesValuePortfolio WeightChange
T. Rowe Price Associates history 730.86K $7.29M 0.00% Hold
Citadel Advisors history 10.05K $100.00K 0.00% Hold
UBS Group AG history 199 $2.00K 0.00% Reduce

Q3 2021 — 3 funds

FundSharesValuePortfolio WeightChange
T. Rowe Price Associates history 730.86K $7.28M 0.00% New
Citadel Advisors history 10.05K $101.00K 0.00% New
UBS Group AG history 1.41K $14.00K 0.00% New

New Positions (latest)

No fund opened a new position this quarter.

Fully Exited (vs previous quarter)

No tracked fund fully exited this quarter.

Fund Position History — shares by quarter (top 3 funds)

FundQ4 2022Q2 2022Q1 2022Q4 2021Q3 2021
UBS Group AG 400 199 799 199 1.41K
Citadel Advisors — — — 10.05K 10.05K
T. Rowe Price Associates — — — 730.86K 730.86K

Download holders (CSV)